Bristol-Myers-Squibb on Bioeconhttps://en.bioecon.ru/companies/bristol-myers-squibb/Recent content in Bristol-Myers-Squibb on BioeconHugoen-USWed, 29 Jul 2026 09:52:30 +0700CAR-T cell therapyhttps://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.Biopharmaceuticals & biomedicineshttps://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.